Although no clinical evidence has been published on the combined use of ERK cascade inhibition and PPARγ activation in tumours [41], current therapeutic regimens inhibit the eicosanoid-mediated activation of the ERK cascade, and in conjunction with PPARγ activation, may provide a basis for differentiation-inducing therapy in combination with classical chemotherapeutics or biologics. This evidence concerns the gene PPARG and neoplasm.